Anti-apoptotic mechanisms of drug resistance in cancer

Current Cancer Drug Targets

Volumn 9, Issue 3, 2009, Pages 307-319

  Wilson, T R ^a   Johnston, P G ^a   Longley, D B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Apoptosis; Cancer; Drug resistance; Therapeutic targeting

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AEG 35156; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; BORTEZOMIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEATH RECEPTOR 4 ANTIBODY; DEATH RECEPTOR 5 ANTIBODY; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FLUDARABINE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LY 2181308; MELPHALAN; NAVELBINE; OBATOCLAX; OBLIMERSEN; PANITUMUMAB; PRO 1762; RECEPTOR ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BINDING; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NONHUMAN; PROSTATE CANCER; REVIEW; SARCOMA; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DRUG RESISTANCE, NEOPLASM; HOMEOSTASIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, DEATH DOMAIN;

EID: 65649132661     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788166547     Document Type: Review

References (190)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70. (Pubitemid 30046295)
2. Kerr, J. F.; Wyllie, A. H.; Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26, 239-257.
3. Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
4. Rathmell, J. C.; Thompson, C. B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002, 109(Suppl.), S97-107. (Pubitemid 34457855)
5. Ashkenazi, A.; Dixit, V. M. Death receptors: signaling and modulation. Science 1998, 281, 1305-1308. (Pubitemid 28406815)
6. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science 1998, 281, 1309-1312. (Pubitemid 28406816)
7. Danial, N. N. BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death. Clin. Cancer Res. 2007, 13, 7254-7263.
8. Zou, H.; Li, Y.; Liu, X.; Wang, X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates pro-caspase-9. J. Biol. Chem. 1999, 274, 11549-11556. (Pubitemid 129518401)
9. Nachmias, B.; Ashhab, Y.; Ben-Yehuda, D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin. Cancer Biol. 2004, 14, 231-243. (Pubitemid 38824584)
10. Srinivasula, S. M.; Gupta, S.; Datta, P.; Zhang, Z.; Hegde, R.; Cheong, N.; Fernandes-Alnemri, T.; Alnemri, E. S. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J. Biol. Chem. 2003, 278, 31469-31472. (Pubitemid 37048322)
11. Wei, M. C.; Zong, W. X.; Cheng, E. H.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A. J.; Roth, K. A.; MacGregor, G. R.; Thompson, C. B.; Korsmeyer, S. J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292, 727-730. (Pubitemid 32385543)
12. Kim, H.; Rafiuddin-Shah, M.; Tu, H. C.; Jeffers, J. R.; Zambetti, G. P.; Hsieh, J. J.; Cheng, E. H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 2006, 8, 1348-1358.
13. Dlugosz, P. J.; Billen, L. P.; Annis, M. G.; Zhu, W.; Zhang, Z.; Lin, J.; Leber, B.; Andrews, D. W. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J. 2006, 25, 2287-2296. (Pubitemid 44012212)
14. Benz, E. J., Jr.; Nathan, D. G.; Amaravadi, R. K.; Danial, N. N. Targeting the cell death-survival equation. Clin. Cancer Res. 2007, 13, 7250-7253.
15. Korsmeyer, S. J.; Wei, M. C.; Saito, M.; Weiler, S.; Oh, K. J.; Schlesinger, P. H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7, 1166-1173. (Pubitemid 32042223)
16. Huang, D. C.; Strasser, A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000, 103, 839-842.
17. Franke, T. F.; Cantley, L. C. Apoptosis. A Bad kinase makes good. Nature 1997, 390, 116-117. (Pubitemid 27507959)
18. Chinnaiyan, A. M.; O'Rourke, K.; Tewari, M.; Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81, 505-512.
19. Yang, X.; Khosravi-Far, R.; Chang, H. Y.; Baltimore, D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997, 89, 1067-1076. (Pubitemid 127678740)
20. Chang, H. Y.; Nishitoh, H.; Yang, X.; Ichijo, H.; Baltimore, D. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 1998, 281, 1860-1863. (Pubitemid 28450508)
21. Liu, J.; Lin, A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005, 15, 36-42. (Pubitemid 41653963)
22. Cascino, I.; Papoff, G.; De Maria, R.; Testi, R.; Ruberti, G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 1996, 156, 13-17. (Pubitemid 26006942)
23. Pitti, R. M.; Marsters, S. A.; Lawrence, D. A.; Roy, M.; Kischkel, F. C.; Dowd, P.; Huang, A.; Donahue, C. J.; Sherwood, S. W.; Baldwin, D. T.; Godowski, P. J.; Wood, W. I.; Gurney, A. L.; Hillan, K. J.; Cohen, R. L.; Goddard, A. D.; Botstein, D.; Ashkenazi, A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396, 699-703. (Pubitemid 29003951)
24. Walczak, H.; Krammer, P. H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 2000, 256, 58-66. (Pubitemid 30211167)
25. Merino, D.; Lalaoui, N.; Morizot, A.; Schneider, P.; Solary, E.; Micheau, O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 2006, 26, 7046-7055.
26. Krueger, A.; Baumann, S.; Krammer, P. H.; Kirchhoff, S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell Biol. 2001, 21, 8247-8254. (Pubitemid 33108586)
27. Araujo, H.; Danziger, N.; Cordier, J.; Glowinski, J.; Chneiweiss, H. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J. Biol. Chem. 1993, 268, 5911-5920. (Pubitemid 23090927)
28. Xiao, C.; Yang, B. F.; Asadi, N.; Beguinot, F.; Hao, C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 2002, 277, 25020-25025.
29. Kitsberg, D.; Formstecher, E.; Fauquet, M.; Kubes, M.; Cordier, J.; Canton, B.; Pan, G.; Rolli, M.; Glowinski, J.; Chneiweiss, H. Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNFalpha- induced apoptosis. J. Neurosci. 1999, 19, 8244-8251. (Pubitemid 30226743)
30. Yang, B. F.; Xiao, C.; Roa, W. H.; Krammer, P. H.; Hao, C. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J. Biol. Chem. 2003, 278, 7043-7050. (Pubitemid 36800700)
31. Liston, P.; Fong, W. G.; Korneluk, R. G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003, 22, 8568-8580. (Pubitemid 38019194)
32. Bratton, S. B.; Cohen, G. M. Death receptors leave a caspase footprint that Smacs of XIAP. Cell Death Differ. 2003, 10, 4-6. (Pubitemid 36511824)
33. Bratton, S. B.; Lewis, J.; Butterworth, M.; Duckett, C. S.; Cohen, G. M. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis. Cell Death Differ. 2002, 9, 881-892.
34. Verhagen, A. M.; Ekert, P. G.; Pakusch, M.; Silke, J.; Connolly, L. M.; Reid, G. E.; Moritz, R. L.; Simpson, R. J.; Vaux, D. L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102, 43-53.
35. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365. (Pubitemid 32467045)
36. Jorissen, R. N.; Walker, F.; Pouliot, N.; Garrett, T. P.; Ward, C. W.; Burgess, A. W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003, 284, 31-53. (Pubitemid 36331965)
37. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19, 3159-3167. (Pubitemid 30428195)
38. Fresno Vara, J. A.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30, 193-204.
39. Lin, A.; Karin, M. NF-kappaB in cancer: a marked target. Semin. Cancer Biol. 2003, 13, 107-114.
40. Burgering, B. M.; Medema, R. H. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc. Biol. 2003, 73, 689-701. (Pubitemid 38040447)
41. Grandis, J. R.; Drenning, S. D.; Zeng, Q.; Watkins, S. C.; Melhem, M. F.; Endo, S.; Johnson, D. E.; Huang, L.; He, Y.; Kim, J. D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 4227-4232. (Pubitemid 30226115)
42. Aoki, Y.; Feldman, G. M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101, 1535-1542. (Pubitemid 36182531)
43. Yu, H.; Jove, R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105. (Pubitemid 38198738)
44. Bakhshi, A.; Jensen, J. P.; Goldman, P.; Wright, J. J.; McBride, O. W.; Epstein, A. L.; Korsmeyer, S. J. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41, 899-906. (Pubitemid 15243395)
45. Tsujimoto, Y.; Cossman, J.; Jaffe, E.; Croce, C. M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228, 1440-1443. (Pubitemid 15041322)
46. Veis, D. J.; Sorenson, C. M.; Shutter, J. R.; Korsmeyer, S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993, 75, 229-240. (Pubitemid 23320287)
47. Nakayama, K.; Negishi, I.; Kuida, K.; Sawa, H.; Loh, D. Y. Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc. Natl. Acad. Sci. USA 1994, 91, 3700-3704. (Pubitemid 2086624)
48. Teixeira, C.; Reed, J. C.; Pratt, M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995, 55, 3902-3907.
49. Tsujimoto, Y. Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 1989, 4, 1331-1336. (Pubitemid 19273387)
50. Letai, A.; Sorcinelli, M. D.; Beard, C.; Korsmeyer, S. J. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004, 6, 241-249. (Pubitemid 39222037)
51. Zhang, L.; Yu, J.; Park, B. H.; Kinzler, K. W.; Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290, 989-992.
52. Heiser, D.; Labi, V.; Erlacher, M.; Villunger, A. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp. Gerontol. 2004, 39, 1125-1135. (Pubitemid 39024362)
53. Linjawi, A.; Kontogiannea, M.; Halwani, F.; Edwardes, M.; Meterissian, S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J. Am. Coll. Surg. 2004, 198, 83-90. (Pubitemid 38201092)
54. Yang, Q.; Sakurai, T.; Yoshimura, G.; Suzuma, T.; Umemura, T.; Nakamura, M.; Nakamura, Y.; Mori, I.; Kakudo, K. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol. Rep. 2003, 10, 121-125.
55. Bukholm, I. R.; Bukholm, G.; Nesland, J. M. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. APMIS 2002, 110, 214-220. (Pubitemid 34454601)
56. Hussain, S. A.; Ganesan, R.; Hiller, L.; Cooke, P. W.; Murray, P.; Young, L. S.; James, N. D. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol. Rep. 2003, 10, 571-576.
57. Maluf, F. C.; Cordon-Cardo, C.; Verbel, D. A.; Satagopan, J. M.; Boyle, M. G.; Herr, H.; Bajorin, D. F. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann. Oncol. 2006, 17, 1677-1686. (Pubitemid 44680889)
58. Miquel, C.; Borrini, F.; Grandjouan, S.; Auperin, A.; Viguier, J.; Velasco, V.; Duvillard, P.; Praz, F.; Sabourin, J. C. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am. J. Clin. Pathol. 2005, 123, 562-570. (Pubitemid 40418551)
59. Veronese, S.; Mauri, F. A.; Caffo, O.; Scaioli, M.; Aldovini, D.; Perrone, G.; Galligioni, E.; Doglioni, C.; Dalla Palma, P.; Barbareschi, M. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int. J. Cancer 1998, 79, 13-18. (Pubitemid 28157719)
60. Casado, S.; Forteza, J.; Dominguez, S.; Abad, M. T.; Perez, I.; Intxaurbe, I.; del Campo, J. M.; Lopez, R. Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma. Am. J. Clin. Oncol. 2002, 25, 588-590. (Pubitemid 35453666)
61. Skirnisdottir, I.; Seidal, T.; Gerdin, E.; Sorbe, B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int. J. Gynecol. Cancer 2002, 12, 265-276.
62. Skirnisdottir, I.; Sorbe, B.; Seidal, T. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 2001, 11, 147-158. (Pubitemid 32381664)
63. van Geelen, C. M.; Westra, J. L.; de Vries, E. G.; Boersma-van Ek, W.; Zwart, N.; Hollema, H.; Boezen, H. M.; Mulder, N. H.; Plukker, J. T.; de Jong, S.; Kleibeuker, J. H.; Koornstra, J. J. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J. Clin. Oncol. 2006, 24, 4998-5004. (Pubitemid 46631402)
64. Min, Y. J.; Lee, J. H.; Choi, S. J.; Chi, H. S.; Lee, J. S.; Kim, W. K.; Lee, K. H. Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk. Res. 2004, 28, 359-365. (Pubitemid 38199943)
65. McCarthy, M. M.; Sznol, M.; DiVito, K. A.; Camp, R. L.; Rimm, D. L.; Kluger, H. M. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin. Cancer Res. 2005, 11, 5188-5194. (Pubitemid 41003705)
66. Strater, J.; Hinz, U.; Walczak, H.; Mechtersheimer, G.; Koretz, K.; Herfarth, C.; Moller, P.; Lehnert, T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 2002, 8, 3734-3740. (Pubitemid 35424763)
67. Sanlioglu, A. D.; Korcum, A. F.; Pestereli, E.; Erdogan, G.; Karaveli, S.; Savas, B.; Griffith, T. S.; Sanlioglu, S. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, 716-723. (Pubitemid 47418395)
68. Han, J. Y.; Hong, E. K.; Choi, B. G.; Park, J. N.; Kim, K. W.; Kang, J. H.; Jin, J. Y.; Park, S. Y.; Hong, Y. S.; Lee, K. S. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med. Oncol. 2003, 20, 355-362. (Pubitemid 38021486)
69. Dong, H. P.; Kleinberg, L.; Silins, I.; Florenes, V. A.; Trope, C. G.; Risberg, B.; Nesland, J. M.; Davidson, B. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 2008, 112, 84-93.
70. Falschlehner, C.; Emmerich, C. H.; Gerlach, B.; Walczak, H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 2007, 39, 1462-1475. (Pubitemid 47031030)
71. Korkolopoulou, P.; Goudopoulou, A.; Voutsinas, G.; Thomas- Tsagli, E.; Kapralos, P.; Patsouris, E.; Saetta, A. A. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004, 63, 1198-1204. (Pubitemid 38746841)
72. Korkolopoulou, P.; Saetta, A. A.; Levidou, G.; Gigelou, F.; Lazaris, A.; Thymara, I.; Scliri, M.; Bousboukea, K.; Michalopoulos, N. V.; Apostolikas, N.; Konstantinidou, A.; Tzivras, M.; Patsouris, E. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 2007, 51, 150-156. (Pubitemid 47083980)
73. Moller, P.; Koretz, K.; Leithauser, F.; Bruderlein, S.; Henne, C.; Quentmeier, A.; Krammer, P. H. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 1994, 57, 371-377. (Pubitemid 24168612)
74. Backus, H. H.; Dukers, D. F.; van Groeningen, C. J.; Vos, W.; Bloemena, E.; Wouters, D.; van Riel, J. M.; Smid, K.; Giaccone, G.; Pinedo, H. M.; Peters, G. J. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol. 2001, 12, 209-216. (Pubitemid 32223870)
75. Bezulier, K.; Fina, F.; Roussel, M.; Bun, S. S.; Ciccolini, J.; Martin, P. M.; Milano, G.; Aubert, C.; Barra, Y. Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines? J. Clin. Pharm. Ther. 2003, 28, 403-408. (Pubitemid 37352450)
76. Lerma, E.; Romero, M.; Gallardo, A.; Pons, C.; Munoz, J.; Fuentes, J.; Lloveras, B.; Catasus, L.; Prat, J. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows. Arch. 2008, 452, 65-74.
77. Bebenek, M.; Dus, D.; Kozlak, J. Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res. 2007, 27, 215-218. (Pubitemid 46363334)
78. Yamana, K.; Bilim, V.; Hara, N.; Kasahara, T.; Itoi, T.; Maruyama, R.; Nishiyama, T.; Takahashi, K.; Tomita, Y. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br. J. Cancer 2005, 93, 544-551. (Pubitemid 43079997)
79. Pernick, N. L.; Sarkar, F. H.; Tabaczka, P.; Kotcher, G.; Frank, J.; Adsay, N. V. Fas and Fas ligand expression in pancreatic adenocarcinoma. Pancreas 2002, 25, e36-41.
80. Bennett, M. W.; O'Connell, J.; Houston, A.; Kelly, J.; O'Sullivan, G. C.; Collins, J. K.; Shanahan, F. Fas ligand upregulation is an early event in colonic carcinogenesis. J. Clin. Pathol. 2001, 54, 598-604. (Pubitemid 32756440)
81. von Reyher, U.; Strater, J.; Kittstein, W.; Gschwendt, M.; Krammer, P. H.; Moller, P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 1998, 58, 526-534. (Pubitemid 28087418)
82. Gratas, C.; Tohma, Y.; Barnas, C.; Taniere, P.; Hainaut, P.; Ohgaki, H. Up-regulation of Fas (APO-1/CD95) ligand and downregulation of Fas expression in human esophageal cancer. Cancer Res. 1998, 58, 2057-2062. (Pubitemid 28232883)
83. Mottolese, M.; Buglioni, S.; Bracalenti, C.; Cardarelli, M. A.; Ciabocco, L.; Giannarelli, D.; Botti, C.; Natali, P. G.; Concetti, A.; Venanzi, F. M. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int. J. Cancer 2000, 89, 127-132. (Pubitemid 30185920)
84. Niehans, G. A.; Brunner, T.; Frizelle, S. P.; Liston, J. C.; Salerno, C. T.; Knapp, D. J.; Green, D. R.; Kratzke, R. A. Human lung carcinomas express Fas ligand. Cancer Res. 1997, 57, 1007-1012. (Pubitemid 27138590)
85. Krammer, P. H. CD95's deadly mission in the immune system. Nature 2000, 407, 789-795.
86. O'Connell, J.; Bennett, M. W.; O'Sullivan, G. C.; Collins, J. K.; Shanahan, F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med. 1997, 3, 294-300. (Pubitemid 27295100)
87. Ryan, A. E.; Shanahan, F.; O'Connell, J.; Houston, A. M. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 2006, 5, 246-249. (Pubitemid 43213492)
88. Botti, C.; Buglioni, S.; Benevolo, M.; Giannarelli, D.; Papaldo, P.; Cognetti, F.; Vici, P.; Di Filippo, F.; Del Nonno, F.; Venanzi, F. M.; Natali, P. G.; Mottolese, M. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res. 2004, 10, 1360-1365. (Pubitemid 38365229)
89. Pernick, N. L.; Biernat, L.; Du, W.; Visscher, D. W. Clinicopathologic Analysis of Fas, Fas Ligand, and Other Biomarkers in Locally Advanced Breast Carcinoma. Breast J. 2000, 6, 233-241. (Pubitemid 30622095)
90. Sjostrom, J.; Blomqvist, C.; von Boguslawski, K.; Bengtsson, N. O.; Mjaaland, I.; Malmstrom, P.; Ostenstadt, B.; Wist, E.; Valvere, V.; Takayama, S.; Reed, J. C.; Saksela, E. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 2002, 8, 811-816. (Pubitemid 34742112)
91. Kushlinskii, N. E.; Britvin, T. A.; Abbasova, S. G.; Perevoshchikov, A. G.; Prorokov, V. V.; Kostanyan, I. A.; Knysh, V. I.; Lipkin, V. M. Soluble Fas antigen in the serum of patients with colon cancer. Bull. Exp. Biol. Med. 2001, 131, 361-363. (Pubitemid 33149834)
92. Ueno, T.; Toi, M.; Tominaga, T. Circulating soluble Fas concentration in breast cancer patients. Clin. Cancer Res. 1999, 5, 3529-3533.
93. Mizutani, Y.; Yoshida, O.; Bonavida, B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J. Urol. 1998, 160, 571-576. (Pubitemid 29476736)
94. Midis, G. P.; Shen, Y.; Owen-Schaub, L. B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996, 56, 3870-3874. (Pubitemid 26284729)
95. Bullani, R. R.; Huard, B.; Viard-Leveugle, I.; Byers, H. R.; Irmler, M.; Saurat, J. H.; Tschopp, J.; French, L. E. Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 2001, 117, 360-364. (Pubitemid 34205723)
96. Ryu, B. K.; Lee, M. G.; Chi, S. G.; Kim, Y. W.; Park, J. H. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. 2001, 194, 15-19. (Pubitemid 32390443)
97. Zhou, X. D.; Yu, J. P.; Liu, J.; Luo, H. S.; Chen, H. X.; Yu, H. G. Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin. Sci. (Lond.) 2004, 106, 397-405. (Pubitemid 38553588)
98. Zhou, X. D.; Yu, J. P.; Chen, H. X.; Yu, H. G.; Luo, H. S. Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer. World J. Gastroenterol. 2005, 11, 2482-2485. (Pubitemid 40667986)
99. Valnet-Rabier, M. B.; Challier, B.; Thiebault, S.; Angonin, R.; Margueritte, G.; Mougin, C.; Kantelip, B.; Deconinck, E.; Cahn, J. Y.; Fest, T. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br. J. Haematol. 2005, 128, 767-773. (Pubitemid 40444868)
100. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58, 5315-5320. (Pubitemid 28551107)
101. Nakamura, M.; Tsuji, N.; Asanuma, K.; Kobayashi, D.; Yagihashi, A.; Hirata, K.; Torigoe, T.; Sato, N.; Watanabe, N. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci. 2004, 95, 44-51. (Pubitemid 38208406)
102. Zangemeister-Wittke, U. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann. N. Y. Acad. Sci. 2003, 1002, 90-94. (Pubitemid 38253333)
103. Tu, S. P.; Jiang, X. H.; Lin, M. C.; Cui, J. T.; Yang, Y.; Lum, C. T.; Zou, B.; Zhu, Y. B.; Jiang, S. H.; Wong, W. M.; Chan, A. O.; Yuen, M. F.; Lam, S. K.; Kung, H. F.; Wong, B. C. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003, 63, 7724-7732. (Pubitemid 37466703)
104. Cao, C.; Mu, Y.; Hallahan, D. E.; Lu, B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23, 7047-7052. (Pubitemid 39319166)
105. Hu, Y.; Cherton-Horvat, G.; Dragowska, V.; Baird, S.; Korneluk, R. G.; Durkin, J. P.; Mayer, L. D.; LaCasse, E. C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 2003, 9, 2826-2836. (Pubitemid 36842129)
106. LaCasse, E. C.; Cherton-Horvat, G. G.; Hewitt, K. E.; Jerome, L. J.; Morris, S. J.; Kandimalla, E. R.; Yu, D.; Wang, H.; Wang, W.; Zhang, R.; Agrawal, S.; Gillard, J. W.; Durkin, J. P. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 2006, 12, 5231-5241. (Pubitemid 44453353)
107. Ambrosini, G.; Adida, C.; Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921. (Pubitemid 27353455)
108. Kato, J.; Kuwabara, Y.; Mitani, M.; Shinoda, N.; Sato, A.; Toyama, T.; Mitsui, A.; Nishiwaki, T.; Moriyama, S.; Kudo, J.; Fujii, Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 2001, 95, 92-95. (Pubitemid 32187079)
109. Zaffaroni, N.; Pennati, M.; Colella, G.; Perego, P.; Supino, R.; Gatti, L.; Pilotti, S.; Zunino, F.; Daidone, M. G. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 2002, 59, 1406-1412.
110. Ye, C. P.; Qiu, C. Z.; Huang, Z. X.; Su, Q. C.; Zhuang, W.; Wu, R. L.; Li, X. F. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J. Gastroenterol. 2007, 13, 6264-6268.
111. Tamm, I.; Richter, S.; Oltersdorf, D.; Creutzig, U.; Harbott, J.; Scholz, F.; Karawajew, L.; Ludwig, W. D.; Wuchter, C. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res. 2004, 10, 3737-3744. (Pubitemid 38697607)
112. Tamm, I.; Richter, S.; Scholz, F.; Schmelz, K.; Oltersdorf, D.; Karawajew, L.; Schoch, C.; Haferlach, T.; Ludwig, W. D.; Wuchter, C. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J. 2004, 5, 489-495. (Pubitemid 40045282)
113. Mizutani, Y.; Nakanishi, H.; Li, Y. N.; Matsubara, H.; Yamamoto, K.; Sato, N.; Shiraishi, T.; Nakamura, T.; Mikami, K.; Okihara, K.; Takaha, N.; Ukimura, O.; Kawauchi, A.; Nonomura, N.; Bonavida, B.; Miki, T. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int. J. Oncol. 2007, 30, 919-925.
114. Kluger, H. M.; McCarthy, M. M.; Alvero, A. B.; Sznol, M.; Ariyan, S.; Camp, R. L.; Rimm, D. L.; Mor, G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J. Transl. Med. 2007, 5, 6. (Pubitemid 46243459)
115. Tanimoto, T.; Tsuda, H.; Imazeki, N.; Ohno, Y.; Imoto, I.; Inazawa, J.; Matsubara, O. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett. 2005, 224, 141-151. (Pubitemid 40720375)
116. Ferreira, C. G.; van der Valk, P.; Span, S. W.; Jonker, J. M.; Postmus, P. E.; Kruyt, F. A.; Giaccone, G. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. 2001, 12, 799-805. (Pubitemid 32655089)
117. Klasa, R. J.; Gillum, A. M.; Klem, R. E.; Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002, 12, 193-213.
118. Frantz, S. Lessons learnt from Genasense's failure. Nat. Rev. Drug Discov. 2004, 3, 542-543. (Pubitemid 39022968)
119. Gleave, M. E.; Monia, B. P. Antisense therapy for cancer. Nat. Rev. Cancer 2005, 5, 468-479. (Pubitemid 40791489)
120. Margolin, K.; Synold, T. W.; Lara, P.; Frankel, P.; Lacey, S. F.; Quinn, D. I.; Baratta, T.; Dutcher, J. P.; Xi, B.; Diamond, D. J.; Gandara, D. R. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J. Cancer Res. Clin. Oncol. 2007, 133, 705-711. (Pubitemid 47319237)
121. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Bociek, R. G.; Pavletic, S.; Rai, K. R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25, 1114-1120. (Pubitemid 46596764)
122. Tolcher, A. W.; Chi, K.; Kuhn, J.; Gleave, M.; Patnaik, A.; Takimoto, C.; Schwartz, G.; Thompson, I.; Berg, K.; D'Aloisio, S.; Murray, N.; Frankel, S. R.; Izbicka, E.; Rowinsky, E. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2005, 11, 3854-3861. (Pubitemid 40685606)
123. Yamanaka, K.; Rocchi, P.; Miyake, H.; Fazli, L.; So, A.; Zangemeister- Wittke, U.; Gleave, M. E. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int. 2006, 97, 1300-1308. (Pubitemid 43907340)
124. Zangemeister-Wittke, U.; Leech, S. H.; Olie, R. A.; Simoes-Wust, A. P.; Gautschi, O.; Luedke, G. H.; Natt, F.; Haner, R.; Martin, P.; Hall, J.; Nalin, C. M.; Stahel, R. A. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 2000, 6, 2547-2555. (Pubitemid 30399227)
125. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305, 1466-1470. (Pubitemid 39167667)
126. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681. (Pubitemid 40825512)
127. Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju, S. R.; Goulet, D.; Viallet, J.; Belec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R. W.; Beauparlant, P.; Shore, G. C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 2007, 104, 19512-19517.
128. McDermott, U.; Longley, D. B.; Galligan, L.; Allen, W.; Wilson, T.; Johnston, P. G. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 2005, 65, 8951-8960. (Pubitemid 41377386)
129. Longley, D. B.; Allen, W. L.; McDermott, U.; Wilson, T. R.; Latif, T.; Boyer, J.; Lynch, M.; Johnston, P. G. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin. Cancer Res. 2004, 10, 3562-3571. (Pubitemid 38685467)
130. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364, 806-809. (Pubitemid 23261761)
131. Rensing-Ehl, A.; Frei, K.; Flury, R.; Matiba, B.; Mariani, S. M.; Weller, M.; Aebischer, P.; Krammer, P. H.; Fontana, A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 1995, 25, 2253-2258.
132. MacEwan, D. J. TNF ligands and receptors - a matter of life and death. Br. J. Pharmacol. 2002, 135, 855-875. (Pubitemid 34214444)
133. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 2000, 18, 1185-1190.
134. Hersh, E. M.; Metch, B. S.; Muggia, F. M.; Brown, T. D.; Whitehead, R. P.; Budd, G. T.; Rinehart, J. J.; Crawford, E. D.; Bonnet, J. D.; Behrens, B. C. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J. Immunother. 1991, 10, 426-431.
135. Vassalli, P.; Grau, G. E.; Piguet, P. F. TNF in autoimmune diseases, graft-versus-host reactions, and pulmonary fibrosis. Immunol. Ser. 1992, 56, 409-430.
136. Lienard, D.; Ewalenko, P.; Delmotte, J. J.; Renard, N.; Lejeune, F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon
137. Renard, N.; Lienard, D.; Lespagnard, L.; Eggermont, A.; Heimann, R.; Lejeune, F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int. J. Cancer 1994, 57, 656-663. (Pubitemid 24201355)
138. Cornett, W. R.; McCall, L. M.; Petersen, R. P.; Ross, M. I.; Briele, H. A.; Noyes, R. D.; Sussman, J. J.; Kraybill, W. G.; Kane, J. M., 3rd; Alexander, H. R.; Lee, J. E.; Mansfield, P. F.; Pingpank, J. F.; Winchester, D. J.; White, R. L., Jr.; Chadaram, V.; Herndon, J. E., 2nd; Fraker, D. L.; Tyler, D. S. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J. Clin. Oncol. 2006, 24, 4196-4201.
139. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104, 155-162.
140. Wajant, H.; Pfizenmaier, K.; Scheurich, P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002, 7, 449-459.
141. Bonavida, B.; Ng, C. P.; Jazirehi, A.; Schiller, G.; Mizutani, Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int. J. Oncol. 1999, 15, 793-802.
142. Shankar, S.; Srivastava, R. K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist. Updat. 2004, 7, 139-156. (Pubitemid 38736066)
143. Gliniak, B.; Le, T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999, 59, 6153-6158. (Pubitemid 30035636)
144. Walczak, H.; Miller, R. E.; Ariail, K.; Gliniak, B.; Griffith, T. S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; Smith, C.; Smolak, P.; Goodwin, R. G.; Rauch, C. T.; Schuh, J. C.; Lynch, D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5, 157-163. (Pubitemid 29068521)
145. Kelley, S. K.; Harris, L. A.; Xie, D.; Deforge, L.; Totpal, K.; Bussiere, J.; Fox, J. A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 2001, 299, 31-38. (Pubitemid 32905115)
146. Straughn, J. M., Jr.; Oliver, P. G.; Zhou, T.; Wang, W.; Alvarez, R. D.; Grizzle, W. E.; Buchsbaum, D. J. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol. Oncol. 2006, 101, 46-54. (Pubitemid 43303558)
147. Buchsbaum, D. J.; Zhou, T.; Grizzle, W. E.; Oliver, P. G.; Hammond, C. J.; Zhang, S.; Carpenter, M.; LoBuglio, A. F. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 2003, 9, 3731-3741. (Pubitemid 37169242)
148. Chuntharapai, A.; Dodge, K.; Grimmer, K.; Schroeder, K.; Marsters, S. A.; Koeppen, H.; Ashkenazi, A.; Kim, K. J. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 2001, 166, 4891-4898. (Pubitemid 32280698)
149. Marini, P.; Denzinger, S.; Schiller, D.; Kauder, S.; Welz, S.; Humphreys, R.; Daniel, P. T.; Jendrossek, V.; Budach, W.; Belka, C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006, 25, 5145-5154. (Pubitemid 44285983)
150. Pukac, L.; Kanakaraj, P.; Humphreys, R.; Alderson, R.; Bloom, M.; Sung, C.; Riccobene, T.; Johnson, R.; Fiscella, M.; Mahoney, A.; Carrell, J.; Boyd, E.; Yao, X. T.; Zhang, L.; Zhong, L.; von Kerczek, A.; Shepard, L.; Vaughan, T.; Edwards, B.; Dobson, C.; Salcedo, T.; Albert, V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 2005, 92, 1430-1441. (Pubitemid 40705010)
151. Voelkel-Johnson, C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol. Ther. 2003, 2, 283-290.
152. Tolcher, A. W.; Mita, M.; Meropol, N. J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N. L.; Halpern, W.; Corey, A.; Cohen, R. B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 2007, 25, 1390-1395. (Pubitemid 46706887)
153. Plummer, R.; Attard, G.; Pacey, S.; Li, L.; Razak, A.; Perrett, R.; Barrett, M.; Judson, I.; Kaye, S.; Fox, N. L.; Halpern, W.; Corey, A.; Calvert, H.; de Bono, J. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 2007, 13, 6187-6194. (Pubitemid 350075080)
154. Longley, D. B.; Wilson, T. R.; McEwan, M.; Allen, W. L.; McDermott, U.; Galligan, L.; Johnston, P. G. c-FLIP inhibits chemotherapy- induced colorectal cancer cell death. Oncogene 2006, 25, 838-848. (Pubitemid 43237702)
155. Kamarajan, P.; Sun, N. K.; Chao, C. C. Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. Biochem. J. 2003, 376, 253-260. (Pubitemid 37487221)
156. Wilson, T. R.; McLaughlin, K. M.; McEwan, M.; Sakai, H.; Rogers, K. M.; Redmond, K. M.; Johnston, P. G.; Longley, D. B. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res. 2007, 67, 5754-5762. (Pubitemid 46985008)
157. Conticello, C.; Pedini, F.; Zeuner, A.; Patti, M.; Zerilli, M.; Stassi, G.; Messina, A.; Peschle, C.; De Maria, R. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J. Immunol. 2004, 172, 5467-5477. (Pubitemid 38542047)
158. Matta, H.; Eby, M. T.; Gazdar, A. F.; Chaudhary, P. M. Role of MRIT/cFLIP in protection against chemotherapy-induced apoptosis. Cancer Biol. Ther. 2002, 1, 652-660.
159. Schimmer, A. D.; Thomas, M. P.; Hurren, R.; Gronda, M.; Pellecchia, M.; Pond, G. R.; Konopleva, M.; Gurfinkel, D.; Mawji, I. A.; Brown, E.; Reed, J. C. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res. 2006, 66, 2367-2375. (Pubitemid 43294952)
160. Hyer, M. L.; Croxton, R.; Krajewska, M.; Krajewski, S.; Kress, C. L.; Lu, M.; Suh, N.; Sporn, M. B.; Cryns, V. L.; Zapata, J. M.; Reed, J. C. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005, 65, 4799-4808. (Pubitemid 40740818)
161. Bilim, V.; Kasahara, T.; Hara, N.; Takahashi, K.; Tomita, Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer 2003, 103, 29-37. (Pubitemid 35424202)
162. Carter, B. Z.; Milella, M.; Tsao, T.; McQueen, T.; Schober, W. D.; Hu, W.; Dean, N. M.; Steelman, L.; McCubrey, J. A.; Andreeff, M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003, 17, 2081-2089. (Pubitemid 37428371)
163. Ansell, S. M.; Arendt, B. K.; Grote, D. M.; Jelinek, D. F.; Novak, A. J.; Wellik, L. E.; Remstein, E. D.; Bennett, C. F.; Fielding, A. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004, 18, 616-623. (Pubitemid 38425878)
164. Kojima, H.; Iida, M.; Yaguchi, Y.; Suzuki, R.; Hayashi, N.; Moriyama, H.; Manome, Y. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 682-685. (Pubitemid 43927048)
165. Zhang, M. C.; Hu, C. P.; Chen, Q.; Xia, Y. Experimental study of antisense oligodeoxynucleotide targeting survivin gene for cisplatin resistant human lung adeno-carcinoma xenograft in nude mice. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006, 31, 717-722. (Pubitemid 44645949)
166. Yang, L.; Mashima, T.; Sato, S.; Mochizuki, M.; Sakamoto, H.; Yamori, T.; Oh-Hara, T.; Tsuruo, T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. 2003, 63, 831-837. (Pubitemid 36231984)
167. Fulda, S.; Wick, W.; Weller, M.; Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8, 808-815.
168. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
169. Herbst, R. S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 21-26. (Pubitemid 38610223)
170. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000, 6, 2053-2063. (Pubitemid 30305105)
171. Bruns, C. J.; Harbison, M. T.; Davis, D. W.; Portera, C. A.; Tsan, R.; McConkey, D. J.; Evans, D. B.; Abbruzzese, J. L.; Hicklin, D. J.; Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000, 6, 1936-1948. (Pubitemid 30305093)
172. Milas, L.; Mason, K.; Hunter, N.; Petersen, S.; Yamakawa, M.; Ang, K.; Mendelsohn, J.; Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 2000, 6, 701-708. (Pubitemid 30111496)
173. Williams, K. J.; Telfer, B. A.; Stratford, I. J.; Wedge, S. R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer 2002, 86, 1157-1161. (Pubitemid 34438090)
174. Huang, S. M.; Li, J.; Armstrong, E. A.; Harari, P. M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2002, 62, 4300-4306.
175. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J., Sr.; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208. (Pubitemid 41079832)
176. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345. (Pubitemid 38944402)
177. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21, 2237-2246. (Pubitemid 46621858)
178. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J., Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290, 2149-2158. (Pubitemid 37432975)
179. Giaccone, G.; Herbst, R. S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R. B.; Schiller, J. H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J. S.; Averbuch, S. D.; Wolf, M. K.; Rennie, P.; Fandi, A.; Johnson, D. H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 2004, 22, 777-784. (Pubitemid 41103588)
180. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 2004, 22, 785-794. (Pubitemid 41103589)
181. Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; Ramlau, R.; Janaskova, T.; Vansteenkiste, J.; Strausz, J.; Manikhas, G. M.; Von Pawel, J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007, 25, 1545-1552. (Pubitemid 46733081)
182. Berenson, J. R.; Ma, H. M.; Vescio, R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. 2001, 28, 626-633. (Pubitemid 33138161)
183. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000.
184. L'Allemain, G. Update on . . . the proteasome inhibitor PS341. Bull. Cancer 2002, 89, 29-30.
185. Schmid, P.; Kuhnhardt, D.; Kiewe, P.; Lehenbauer-Dehm, S.; Schippinger, W.; Greil, R.; Lange, W.; Preiss, J.; Niederle, N.; Brossart, P.; Freier, W.; Kummel, S.; Van de Velde, H.; Regierer, A.; Possinger, K. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann. Oncol. 2008, 19, 871-876.
186. Davies, A. M.; Ruel, C.; Lara, P. N.; Lau, D. H.; Gumerlock, P. H.; Bold, R.; Shibata, S.; Lenz, H. J.; Schenkein, D. P.; Gandara, D. R. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J. Thorac. Oncol. 2008, 3, 68-74.
187. Dreicer, R.; Petrylak, D.; Agus, D.; Webb, I.; Roth, B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen- independent prostate cancer. Clin. Cancer Res. 2007, 13, 1208-1215. (Pubitemid 46424062)
188. Lu, Y.; Wang, H.; Mills, G. B. Targeting PI3K-AKT pathway for cancer therapy. Rev. Clin. Exp. Hematol. 2003, 7, 205-228. (Pubitemid 37466220)
189. Mitsiades, C. S.; Mitsiades, N.; Koutsilieris, M. The Akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 2004, 4, 235-256. (Pubitemid 38560073)
190. Xu, L.; Huang, C. C.; Huang, W.; Tang, W. H.; Rait, A.; Yin, Y. Z.; Cruz, I.; Xiang, L. M.; Pirollo, K. F.; Chang, E. H. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 2002, 1, 337-346.